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The ﬁrst successful closed-chest deﬁbrillation of a human
was described by Zoll et al. (1) in 1956. Soon after, the
utility of external cardioversion for nonlethal arrhythmias
was explored (2) and would with time become a routine
intervention in the treatment of atrial ﬁbrillation (AF). The
great majority of patients with AF who were treated with
cardioversion in the original reports had a history of rheu-
matic mitral valve disease, such that a high risk of throm-
boembolic complications was well understood (3). To reduce
this risk, patients with mitral stenosis undergoing car-
dioversion “were generally treated with anticoagulant drugs
for three to four weeks” (3) beforehand. Eventually, this
practice would be applied to all cardioversions for AF except
those with a very short duration of arrhythmia.See page 1082Thus, anticoagulation practices surrounding cardioversion
have, since the advent of the procedure, been empirical but
based on a known risk of a serious complication. None-
theless, the original approach was mechanistically validated
by transesophageal echocardiography (TEE) studies in the
1990s (4,5), and moderately large case series have consis-
tently shown that standard use of a vitamin K antagonist for
3 to 4 weeks before cardioversion (or shorter periods if
preceded by a negative TEE) will result in thromboembolic
rates of <1% within 30 days (6,7).
Three novel oral anticoagulant drugs (NOACs) have been
approved for prevention of stroke in patients with AF over
the past few years, each showing at least noninferiority to
warfarin in overall rates of stroke or systemic embolism
(8–10). Given the entrenched role of vitamin K antagonists
in cardioversion, there has been understandable curiosity*Editorials published in the Journal of the American College of Cardiology reﬂect the
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In this issue of the Journal, Flaker et al. (11) make an
important contribution to our limited but growing knowl-
edge of this topic. Their report describes the outcomes of 743
cardioversions in 540 patients during the ARISTOTLE
(Apixaban for Reduction in Stroke and Other Thromboem-
bolic Events in Atrial Fibrillation) trial. The patients had
been enrolled in the trial for a mean of >6 months before
their ﬁrst cardioversion, and TEE was performed before
cardioversion in w27% of cases with no thrombi observed.
Although the investigators had the option to switch each
patient to open-label warfarin for the cardioversion, patients
remained on their blinded study drug 80% to 85% of the time.
The authors observed no strokes or embolic events within
30 days, regardless of the anticoagulant used. Myocardial
infarction, major bleeding, and death occurred rarely within
30 days and did not differ between patients randomized to
apixaban and those randomized to warfarin. Given that no
strokes or systemic emboli occurred, it made no difference
whether the data were analyzed in an intent-to-treat or on-
treatment manner.
With this report from the ARISTOTLE trial, each of the
major randomized trials of the currently approved NOACs has
now reported on outcomes after cardioversion (in the case of
ROCKET-AF [An Efﬁcacy and Safety Study of Rivaroxaban
WithWarfarin for the Prevention of Stroke and Non-Central
Nervous System Systemic Embolism in Patients With Non-
Valvular Atrial Fibrillation], outcomes after either car-
dioversion or AF ablation were reported) (12,13). In all 3 cases,
only a minority of patients enrolled in the trial ever had a car-
dioversion, with the largest experience of 1,983 procedures
coming from the RE-LY (Randomized Evaluation of Long
Term Anticoagulant Therapy) trial. This reﬂects the
predominance of persistent/permanent AF in these study
populations. In all 3 series, the 30-day incidence of stroke/
systemic embolism was <1% and did not differ whether the
patient was treated with an NOAC or a vitamin K antagonist.
The study fromFlaker et al. (11) has a fewminor limitations
that do not signiﬁcantly detract from the main ﬁndings. First,
given the low expected event rate after cardioversion and the
limited number of observed procedures, this analysis did not
have sufﬁcient statistical power to ﬁnd a small difference in
outcomes between the warfarin and apixaban groups, and no
strict deﬁnition of noninferiority was proposed or met.
Nonetheless, the reported experience was large enough to rule
out any large difference in the safety of cardioversion with
apixaban as compared with warfarin, and the results are
certainly reassuring. Second, the data collection forms were
either designed or interpreted in such a way that the authors
could not be certain that all of the cardioversions recorded
were actually performed for AF. This probably has no bearing
on the primary endpoint, but the reported secondary
endpoints may need to be interpreted with caution as a result.
What we have learned from the current study, as well as
the RE-LY and ROCKET-AF trials, is that cardioversions
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1089performed in the carefully controlled setting of a phase 3
randomized controlled clinical trial are associated with a low
risk of embolic complications that probably does not differ
whether the patient is treated with warfarin or any of the
NOACs. For patients who have been treated with an
NOAC for months and seem reliable with respect to
adherence, there would appear to be no justiﬁcation for
switching them to warfarin if a cardioversion is planned.
Where we still lack information is the common clinical
scenario of a patient newly diagnosed with persistent AF,
where a cardioversion is planned and the clinician and
patient must choose between warfarin or 1 of the NOACs.
Is apixaban more, less, or equally effective compared with
warfarin in this circumstance? Should TEE be performed?
Is 3 to 4 weeks of oral anticoagulation before cardioversion
enough? The available data suggest that apixaban (or another
NOAC) should be no less effective than warfarin for this
purpose, but the available data do not provide deﬁnitive
answers; thus, additional research in this area is needed. In
the meantime, clinical practice, as it has since the 1960s, will
have to remain based at least partly on our best judgment.
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